E
IOBT

Ergoteles’s IO Biotech IOBT Stock Holding History

Ergoteles’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,126
Closed -$59K – 1811
2022
Q1 		$59K Buy
+11,126
New +$73.5K ﹤0.01% 1148

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's IOBT Position: Q2 2022 in Review

Ergoteles sold out of IO Biotech (IOBT) in Q2 2022, closing a stake of 11,126 shares — an estimated $59K sold.

Ergoteles first reported a position in IOBT in Q1 2022 and held it in 1 quarter. The position peaked at $59K in Q1 2022. 18 funds tracked by Wall St. Rank hold IOBT as of Q2 2022.

  • Ergoteles reported no remaining IO Biotech position as of Q2 2022 after selling out during the quarter.
  • Ergoteles sold 11,126 IO Biotech shares in Q2 2022, an estimated $59K.
  • Ergoteles first reported a position in IO Biotech in Q1 2022 and held it in 1 quarter.
  • Ergoteles's IO Biotech position peaked at $59K in Q1 2022.
  • 18 funds tracked by Wall St. Rank held IO Biotech as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.